Please ensure Javascript is enabled for purposes of website accessibility

3 Key Takeaways From Teladoc's Q2 Earnings

By Justin Pope – Aug 1, 2021 at 7:22AM

Key Points

  • The stock has trailed the S&P 500 during 2021.
  • Visit traffic is growing, even compared to its massive 2020 growth spurt.
  • Personalized digital offerings Primary360 and myStrength are building steam and are the real long-term story for Teladoc.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The telemedicine company is down significantly in recent months. What do its most recent results say about a potential comeback?

Telehealth company Teladoc Health (TDOC 5.09%) is down 44% over the past six months, underperforming the broader stock market. The company recently reported its Q2 earnings for the 2021 fiscal year, and investors are wondering whether it's positioned for a comeback. Here are three key takeaways from earnings that might signal brighter days ahead for shareholders.

1. Business is holding up well against COVID-19 comparables

The pandemic forced people to make sudden and dramatic changes to their lives, one of which was the rapid adoption of telehealth. While patients were largely shut out of office visits, Teladoc saw a large surge in its business -- in Q2 2020, when the first wave of the pandemic was at its height, Teladoc's U.S. paid memberships grew to 51.5 million, up 92% from 2019. Visits grew 203% year over year to more than 2.7 million. This fueled 85% revenue growth to $241 million over 2019.

This huge uptick in business created tough comparable numbers for 2021, with many investors fearing that Teladoc would certainly see its business reverse after such a big 2020. Instead, Teladoc has continued to grow, and while Q2 2021 paid U.S. memberships only increased 1% to 52 million, visits grew 28% over 2020. Revenue accelerated from last year, hitting $503 million, a year-over-year increase of 109%.

Elderly patient consulting with a doctor online.

Image source: Getty Images.

The pandemic continues as the delta variant spreads. Still, with much of the U.S. having resumed in-office visits and procedures, all of this solid activity on the back of a tremendous 2020 could signal that Teladoc's business is not a pandemic-driven fluke after all.

2. The underlying business is profitable

Investors are looking for the company's financials to improve as Teladoc grows. Management reported a net loss of $133.8 million for the 2021 second quarter, wider than the loss of $25.7 million from a year ago.

But looking closer at the numbers will reveal many special charges related to Teladoc's merger with Livongo last summer, including stock-based compensation and accounting charges. Teladoc posted a $66.8 million profit on an adjusted EBITDA basis, up 154% from a year ago.

As Teladoc gets bigger, revenue continues to expand faster than the company's expenses. This shows up in the gross margin, which was 68.1% in Q2 2021 versus 62.3% the prior year. Investors should look to see whether gross margin continues to improve in the quarters to come.

3. Primary360 and myStrength are the future

Telehealth is a competitive field and is seen by some as a commodity, which may have hurt investor sentiment toward Teladoc over the past year. But the real story behind Teladoc is the chronic care systems the company is building.

In 2015, Teladoc acquired online counseling and therapy services company BetterHelp for $4 million, and more recently, in 2020, Livongo, a data-based chronic care treatment company, for $18.5 billion. Combining these companies' technology with Teladoc's telehealth network has resulted in the company's personalized, "whole-person" care services -- Primary360 for general health and myStrength for mental health.

These programs are just beginning to roll out, so they'll play a more significant role in the company's results in 2022 and beyond. Meanwhile, Teladoc is continuing to leverage its existing network to build relationships. It signed a deal with health insurer Health Care Service Corporation to give that company's 17 million insured members access to Teladoc's whole-person healthcare services.

It's still too early to determine how successful Teladoc will be with Primary360 and myStrength. Investors will need to monitor enrollment growth over the coming quarters.

Is Teladoc a buy?

The stock is near 52-week lows after its steady six-month decline. Management is forecasting full 2021 revenue at $2 billion, so Teladoc's price-to-sales ratio is 11.5. This seems like an inexpensive valuation for a company growing revenue at 109% and operating in the massive healthcare space.

On the other hand, the valuation also signals that investors are not yet sold on Teladoc's ability to execute its goals regarding personalized healthcare. This valuation could provide a margin of safety for investors, as the steep decline is already pricing in a bit of failure -- meaning success could result in strong returns. Only time will tell, but Teladoc seems to be heading in the right direction after this quarter.

Justin Pope owns shares of Teladoc Health. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health Stock Quote
Teladoc Health
$28.51 (5.09%) $1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.